Lode HN - Search Results

1

Induction of persistent tumor-protective immunity in mice cured of established colon carcinoma metastases.

Xiang R, Lode HN, Dreier T, Gillies SD, Reisfeld RA. Xiang R, et al. Among authors: lode hn. Cancer Res. 1998 Sep 1;58(17):3918-25. Cancer Res. 1998. PMID: 9731503

2

Targeted therapy with a novel enediyene antibiotic calicheamicin theta(I)1 effectively suppresses growth and dissemination of liver metastases in a syngeneic model of murine neuroblastoma.

Lode HN, Reisfeld RA, Handgretinger R, Nicolaou KC, Gaedicke G, Wrasidlo W. Lode HN, et al. Cancer Res. 1998 Jul 15;58(14):2925-8. Cancer Res. 1998. PMID: 9679947

3

Suppression of human prostate carcinoma metastases in severe combined immunodeficient mice by interleukin 2 immunocytokine therapy.

Dolman CS, Mueller BM, Lode HN, Xiang R, Gillies SD, Reisfeld RA. Dolman CS, et al. Among authors: lode hn. Clin Cancer Res. 1998 Oct;4(10):2551-7. Clin Cancer Res. 1998. PMID: 9796990

4

Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases.

Lode HN, Moehler T, Xiang R, Jonczyk A, Gillies SD, Cheresh DA, Reisfeld RA. Lode HN, et al. Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1591-6. doi: 10.1073/pnas.96.4.1591. Proc Natl Acad Sci U S A. 1999. PMID: 9990069 Free PMC article.

5

Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12.

Lode HN, Xiang R, Duncan SR, Theofilopoulos AN, Gillies SD, Reisfeld RA. Lode HN, et al. Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8591-6. doi: 10.1073/pnas.96.15.8591. Proc Natl Acad Sci U S A. 1999. PMID: 10411920 Free PMC article.

6

T cell memory against colon carcinoma is long-lived in the absence of antigen.

Xiang R, Lode HN, Gillies SD, Reisfeld RA. Xiang R, et al. Among authors: lode hn. J Immunol. 1999 Oct 1;163(7):3676-83. J Immunol. 1999. PMID: 10490962

7

Melanoma immunotherapy by targeted IL-2 depends on CD4(+) T-cell help mediated by CD40/CD40L interaction.

Lode HN, Xiang R, Pertl U, Förster E, Schoenberger SP, Gillies SD, Reisfeld RA. Lode HN, et al. J Clin Invest. 2000 Jun;105(11):1623-30. doi: 10.1172/JCI9177. J Clin Invest. 2000. PMID: 10841521 Free PMC article.

8

Targeted cytokines for cancer immunotherapy.

Lode HN, Reisfeld RA. Lode HN, et al. Immunol Res. 2000;21(2-3):279-88. doi: 10.1385/IR:21:2-3:279. Immunol Res. 2000. PMID: 10852128

9

Protective immunity against human carcinoembryonic antigen (CEA) induced by an oral DNA vaccine in CEA-transgenic mice.

Xiang R, Silletti S, Lode HN, Dolman CS, Ruehlmann JM, Niethammer AG, Pertl U, Gillies SD, Primus FJ, Reisfeld RA. Xiang R, et al. Among authors: lode hn. Clin Cancer Res. 2001 Mar;7(3 Suppl):856s-864s. Clin Cancer Res. 2001. PMID: 11300483

10

Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma.

Niethammer AG, Xiang R, Ruehlmann JM, Lode HN, Dolman CS, Gillies SD, Reisfeld RA. Niethammer AG, et al. Among authors: lode hn. Cancer Res. 2001 Aug 15;61(16):6178-84. Cancer Res. 2001. PMID: 11507070

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

147 results

Search Page

Filters